Parabilis Medicines (NASDAQ:PBLS) Shares Climb 9.1% – Still a Buy?

Parabilis Medicines, Inc. (NASDAQ:PBLS) traded up 9.1% during mid-day trading on Tuesday. The stock traded as high as $29.73 and last traded at $29.73. 108,796 shares were traded during trading, a decline of 87% from the average daily volume of 815,535 shares. The stock had previously closed at $27.25.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PBLS. Evercore assumed coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They set an “outperform” rating on the stock. Bank of America assumed coverage on shares of Parabilis Medicines in a research note on Monday, July 6th. They issued a “buy” rating and a $45.00 target price for the company. Lifesci Capital raised shares of Parabilis Medicines to a “strong-buy” rating in a research note on Monday, July 6th. Zacks Research raised shares of Parabilis Medicines to a “hold” rating in a report on Tuesday, July 7th. Finally, HC Wainwright started coverage on Parabilis Medicines in a report on Thursday, October 22nd. They set a “buy” rating and a $40.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.25.

Parabilis Medicines Price Performance

The firm has a market cap of $3.57 billion and a P/E ratio of -13.55. The business’s 50-day moving average price is $32.72.

Parabilis Medicines (NASDAQ:PBLS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($0.16) by ($2.16). The firm had revenue of $0.15 million for the quarter. As a group, research analysts expect that Parabilis Medicines, Inc. will post -2.60 earnings per share for the current year.

Institutional Trading of Parabilis Medicines

A number of institutional investors have recently bought and sold shares of the business. ARCH Venture Management LLC acquired a new position in shares of Parabilis Medicines in the 2nd quarter valued at $175,517,789. venBio Partners LLC acquired a new stake in shares of Parabilis Medicines in the 2nd quarter valued at approximately $144,149,497. Alphabet Inc. bought a new position in Parabilis Medicines during the 2nd quarter worth approximately $134,647,000. Regeneron Pharmaceuticals Inc. bought a new position in Parabilis Medicines during the 2nd quarter worth approximately $114,042,000. Finally, Jupiter Topco LLC bought a new position in Parabilis Medicines during the 2nd quarter worth approximately $62,710,000.

Parabilis Medicines Company Profile

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.